Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) EBIT Margin (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed EBIT Margin for 4 consecutive years, with 2359.23% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin fell 70351.0% to 2359.23% in Q3 2025 year-over-year; TTM through Sep 2025 was 2669.91%, a 39922.0% decrease, with the full-year FY2024 number at 2437.49%, down 57133.0% from a year prior.
  • EBIT Margin was 2359.23% for Q3 2025 at Orchestra BioMed Holdings, down from 2311.84% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 69.94% in Q3 2022 to a low of 6591.7% in Q4 2024.
  • A 4-year average of 2245.76% and a median of 2166.97% in 2024 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: tumbled -387272bps in 2023, then soared 181062bps in 2024.
  • Orchestra BioMed Holdings' EBIT Margin stood at 891.02% in 2022, then crashed by -435bps to 4763.74% in 2023, then plummeted by -38bps to 6591.7% in 2024, then soared by 64bps to 2359.23% in 2025.
  • Per Business Quant, the three most recent readings for OBIO's EBIT Margin are 2359.23% (Q3 2025), 2311.84% (Q2 2025), and 2179.84% (Q1 2025).